The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlation of CA 27.29 and circulating tumor cells before, at the end, and 2 years after adjuvant chemotherapy in patients with primary breast cancer: The SUCCESS trial.
P. G. M. Hepp
Honoraria - Chugai Pharma
B. K. Rack
No relevant relationships to disclose
H. Tesch
No relevant relationships to disclose
M. Rezai
No relevant relationships to disclose
T. Beck
No relevant relationships to disclose
J. Salmen
No relevant relationships to disclose
U. Andergassen
No relevant relationships to disclose
U. Ortmann
No relevant relationships to disclose
T. Zwingers
No relevant relationships to disclose
M. W. Beckmann
No relevant relationships to disclose
W. Lichtenegger
No relevant relationships to disclose
J. W. Janni
Research Funding - Chugai Pharma; Johnson & Johnson; Lilly; Novartis; Pfizer; Sanofi